Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22938912 | 0.78 | PGR (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24359141 | 0.78 | NR3C2 (0.38) | — | |
| SCHEMBL27668201 | 0.77 | HSD11B1 (0.43) | NISCHP2RY1 | |
| SCHEMBL17175213 | 0.77 | NISCH (0.52) | NISCHP2RY1HTR1AALDH1A1ABCG2 | |
| SCHEMBL22938911 | 0.74 | ABCB1 (0.35) | XIAP | |
| SCHEMBL4081801 | 0.73 | SLC6A2 (0.48) | — | |
| SCHEMBL13209385 | 0.72 | P2RY1 (0.40) | NISCHP2RY1ALDH1A1ABCG2ITGB2 | |
| SCHEMBL13228158 | 0.72 | NISCH (0.37) | NISCHP2RY1PIK3CD | |
| SCHEMBL27659846 | 0.71 | SLC6A2 (0.41) | — | |
| SCHEMBL12660327 | 0.71 | ABCG2 (0.39) | P2RX4HTR1AALDH1A1ABCG2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | CYP11B2, CYP11B1, SLC10A1 | NISCH 1089/4885P2RY1 929/4885P2RX4 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.